Learn About Anaplastic Large Cell Lymphoma

What is the definition of Anaplastic Large Cell Lymphoma?
Anaplastic large cell lymphoma (ALCL) is a rare type of Non-Hodgkins lymphoma. Lymphoma is a cancer of the lymph system, part of our immune system. Non-Hodgkins lymphoma involves abnormal growth of white blood cells, either T cells or B cells. Anaplastic large cell lymphoma is an aggressive cancer that usually involves the T-cells. Cancer cells in ALCL can be identified by their appearance under the microscope and by the presence of a tumor marker called CD30 or Ki-1. There are two types of ALCL, a type that affects mainly the skin (cutaneous ALCL) and a type that affects other body organs (systmic ALCL). Systemic ALCL also has two types, ALK-positive (anaplastic lymphoma kinase) and ALK-negative. ALK-positive ALCL occurs more often in children and young adults. ALK-negative ALCL tends to occur in older adults. The symptoms of cutaneous ALCL include red skin lesions that break open and do not heal. Sometimes cutaneous ALCL is also found in the lymph nodes. The symptoms of systemic ALCL include fever, night sweats, and weight loss (B symptoms). The cancer can be found in the bone, soft tissue, spleen, liver and skin. The cause of ALCL is unknown. One type of ALK-negative ALCL has been associated with breast implants. ALCL is diagnosed by a biopsy of the tumor or abnormal skin and examination of the tumor cells under a microscope. Additional testing including PET scans, CT scans, MRI and a bone marrow biopsy can tell doctors if the cancer has spread to other organs.[15060
Save information for later
Sign Up
What are the alternative names for Anaplastic Large Cell Lymphoma?
  • Anaplastic large cell lymphoma
  • ALCL
Who are the top Anaplastic Large Cell Lymphoma Local Doctors?
JZ
Dr. Jasmine M. Zain
Hematology | Oncology | Hematology Oncology
Elite
Highly rated in
22
conditions
Hematology
Oncology
Hematology Oncology

Duarte

1500 E Duarte Rd 
Duarte, CA 91010

Jasmine Zain is a Hematologist and an Oncologist in Duarte, California. Dr. Zain has been practicing medicine for over 35 years and is rated as an Elite doctor by MediFind in the treatment of Anaplastic Large Cell Lymphoma. She is also highly rated in 22 other conditions, according to our data. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Cutaneous T-Cell Lymphoma CTCL. She is licensed to treat patients in New York and California.

View Profile
SH
Dr. Steven M. Horwitz
Oncology
Elite
Highly rated in
29
conditions
Oncology

Memorial Hematology Lymphoma Group

1275 York Ave 
New York, NY 10021

Steven Horwitz is an Oncologist in New York, New York. Dr. Horwitz has been practicing medicine for over 29 years and is rated as an Elite doctor by MediFind in the treatment of Anaplastic Large Cell Lymphoma. He is also highly rated in 29 other conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Cutaneous T-Cell Lymphoma CTCL. He is licensed to treat patients in New York. Dr. Horwitz is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
AS
Dr. Andrei R. Shustov
Hematology Oncology | Oncology
Elite
Highly rated in
26
conditions
Hematology Oncology
Oncology

825 Eastlake Avenue E 
Seattle, WA 98109

Andrei Shustov is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Shustov has been practicing medicine for over 29 years and is rated as an Elite doctor by MediFind in the treatment of Anaplastic Large Cell Lymphoma. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, and Non-Hodgkin Lymphoma. He is licensed to treat patients in Washington. Dr. Shustov is currently accepting new patients.

View Profile
View All Doctors
What are the latest Anaplastic Large Cell Lymphoma Clinical Trials?
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Who is this study for: Adult patients with Non-Melanoma Skin Cancer (NMSC) or Lymphoma
Status: Recruiting
Start Date: September 18, 2017
Intervention Type: Biological, Other
Study Drugs: Nivolumab, Talimogene Laherparepvec
Phase: Phase 2
View Trial
Summary: This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Who is this study for: Adult patients with Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Status: Active, not recruiting
Start Date: September 2014
Intervention Type: Drug
Study Drugs: Bendamustine
Phase: Phase 1
View Trial
Summary: This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma. CPI-613 may kill cancer cells by turning off their mitochondria, which are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By sh...
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Anaplastic Large Cell Lymphoma?
Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma.
Condition: Primary Bone Lymphoma (PBL)
Journal: Zhongguo shi yan xue ye xue za zhi
Treatment Used: Chemotherapy and Radiotherapy or Stem Cell Transplantation
Number of Patients: 21
Published: February 06, 2022
View publication
Summary: Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma.
Operating room environment assessment and biofilm risk for breast implants. A case series.
Journal: Annali italiani di chirurgia
Published: November 19, 2021
View publication
Summary: Operating room environment assessment and biofilm risk for breast implants. A case series.
Tired of the same old research?
Check Latest Advances
What Do Clinicians and Organizations Owe Patients With Recalled Implanted Devices or Materials?
Journal: AMA journal of ethics
Published: October 28, 2021
View publication
Summary: What Do Clinicians and Organizations Owe Patients With Recalled Implanted Devices or Materials?
View All Latest Advances